A pharmaceutical company is developing a novel anticoagulant to prevent stroke in patients with atrial fibrillation. They plan to enroll 500 patients, assigning them to either the investigational drug or a control regimen. To minimize selection bias and to ensure valid comparisons between groups, the study involves a concurrent control group and a randomized assignment process. Which of the following study designs best incorporates these methodological features?